Swift celebrates 20 years, contributes to over 10% of Maruti Suzuki sales
Maruti Suzuki is celebrating 20 years of its Swift in the Indian market. The sporty hatchback was first introduced back in May 2005 and has sold over 3 million units till now in the Indian market. Currently, the Swift has a 31 per cent market share and contributes to over 10 per cent of Maruti Suzuki's sales.
Throughout its 20-year history, the Swift has consistently progressed and improved. By introducing a fresh perspective to the sporty hatchback category in 2005, the Swift became a remarkable success with because of its design and premium features. The 2nd Generation Swift, launched in 2011, was designed to be lighter and more nimble, reinforcing its reputation as a sporty hatchback. The 3rd Generation Swift, released in 2018, brought advanced technological features and catered to changing customer demands. In 2024, the 4th Generation Swift unveiled a new aspect of the Swift's iconic styling, along with the Z-Series engine
The 4th Generation Swift is distinguished by its modern exterior which still retains the iconic sillouhitte of the original Swift. There is a wrap-around character line, a glossy black front grille, and smoky LED projector headlights. The Swift's interior, is driver-focused with a flat-bottomed steering wheel, and sporty asymmetrical instrument cluster dials, among other elements.
Commenting on the occasion, Mr. Partho Banerjee, Senior Executive Officer, Marketing and Sales, Maruti Suzuki India Limited, said, 'The Swift is an icon in its own right. Celebrated by over 3 million customers in India alone, the Swift is an expression of fun and freedom. The Swift has set new benchmarks over the years with every new model, improving on the inherent 'fun-to-drive' DNA. This ever so special nature of the Swift has ensured that nearly one out of every four Swift owners come back to buy another Swift. Today, it enjoys an admirable 31% market share in its segment, contributing to over 10% of MSIL sales. On this special 20-year anniversary, we would like to thank all our customers for their unwavering love for brand Swift."
Check out Upcoming Cars in India 2024, Best SUVs in India.
First Published Date:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
30 minutes ago
- Time of India
Agentic AI: From global hype to enterprise readiness
In a world of accelerating digital decisions, enterprises are beginning to ask not just what AI can do, but what it should initiate on its own. That's where agentic AI enters the conversation. Unlike traditional AI systems that passively respond to prompts, agentic AI systems are designed to act with intention, initiating tasks, adapting to context, and collaborating across systems to fulfill defined goals. In theory, this unlocks immense potential. In practice, especially within enterprise settings, agentic AI introduces a new set of questions around trust, control, and accountability. The global narrative is evolving fast. Yet when viewed through the lens of Indian enterprises, where priorities remain grounded in regulatory compliance, operational efficiency, and explainability, a different picture emerges. Autonomy with purpose The term 'agentic' borrows from cognitive science, referring to systems that can make decisions, pursue goals, and modify their behavior based on outcomes. Applied to AI, this translates into intelligent agents that move beyond generating insights to acting on them, navigating workflows, triggering processes, or interacting with other systems autonomously. Crucially, these agents are not designed to replace humans but to work alongside them, handling high-volume, routine decisions while allowing humans to intervene in moments of nuance or consequence. This distinction is key to enterprise adoption. Across global markets, agentic AI is in an experimental phase. Tech leaders are piloting agents that support tasks like research synthesis, fraud triage, customer issue resolution, and even limited supply chain rebalancing. The potential to reduce decision latency and extend human capacity is clear. Deepak Ramanathan, Vice President, Global Technology Practice, SAS. But early adopters are also uncovering hard boundaries. How do you calibrate autonomy when outcomes have regulatory impact? Can you explain decision paths in systems that learn and evolve? Who remains accountable when agents operate beyond visibility? These are not just technical questions but structural ones. And they define how organizations will progress from prototypes to production. In India, AI interest is surging but agentic AI remains a nascent concept. Organisations are still solidifying their data foundations, automating core processes, and building AI maturity across departments. The emphasis, rightly, is on value, clarity, and control. That's not to say agentic AI doesn't have a role. On the contrary, India's operational scale and appetite for leapfrogging legacy systems could make it fertile ground for agentic models, if they're designed with local realities in mind: Systems must work across fragmented data environments. AI agents must be transparent in how they operate. Human oversight cannot be an afterthought—it must be embedded. In essence, Indian enterprises don't just need smart agents—they need accountable collaborators to help address these key factors that hinge on the successful implementation of agentic AI. The opportunity shift from assistants to agents W here agentic AI stands out is in its ability to orchestrate complexity across enterprise environments. Imagine intelligent agents that can analyze real-time fraud signals, detect anomalies, and trigger rule-based interventions without manual oversight. These agents can also monitor customer journeys, recognize patterns of drop-off, and autonomously adjust outreach strategies to improve engagement. In compliance functions, they can assist teams by compiling audit trails or escalating potential policy breaches based on predefined thresholds. These are not futuristic concepts but natural evolutions of current workflows. What's changing is the proactive role AI can now play. The real opportunity lies not just in automation, but in enabling calibrated and context-aware autonomy. For that, enterprises will need platforms that are not only technically capable but built with governance, transparency, and ethical alignment at their core. The true value of agentic AI will come not from unchecked independence, but from intelligent systems designed to collaborate with humans—augmenting judgment, not replacing it. To achieve this, AI agents must be built with bounded autonomy, guided by three foundational principles. First is decisioning– the use of hybrid intelligence that combines deterministic analytics with reasoning models to ensure decisions are both accurate and auditable. Second is achieving the right human-AI balance, where agents are empowered to act independently only when tasks are well-defined and risk thresholds are acceptable, deferring to human intervention when context or complexity demands it. And third is governance, ensuring every action taken by an agent is aligned with data privacy policies, ethical standards, and industry-specific compliance frameworks. The goal is not to build systems that replace people, but ones where autonomy operates in service of responsibility and trust becomes a design feature, not an afterthought. Autonomy with accountability is the future Agentic AI represents a bold frontier—but not one built on hype alone. Its success hinges on trust, governance, and the ability to embed AI into real-world decisions that matter. For Indian enterprises navigating transformation at scale, the message is clear: Don't chase autonomy for its own sake. Design it to reflect your values, amplify your decisions, and accelerate your goals. The next era of AI isn't just generative. It's agentic. And it's here to work with you.
Time of India
30 minutes ago
- Time of India
Big money is making a beeline for Indian hospitals
Indian hospitals are the new goldmine for deep pockets. Besides a rush of investment, a high-intensity consolidation is ongoing in India's hospital space. As per an ET report based on information from sources, IPO-bound Manipal Health Enterprises is leading the race to acquire Sahyadri Hospitals with a Rs 6,838 crore ($800 million) bid. Global investment firm Blackstone is a close second, sources said. IHH Healthcare-backed Fortis Healthcare and EQT Partners also submitted bids on June 23, which was the last day to submit binding financial bids. Also Read: Manipal Health Enterprises leads race to buy Sahyadri Hospitals The Pune-headquartered hospital chain, which operates 11 facilities across Pune, Nashik, Ahilya Nagar and Karad, comprising 1,300 beds, 2,500 clinicians and 3,500 support staff, is owned by Canada's pension fund Ontario Teachers' Pension Plan (OTPP), which had acquired Sahyadri from Everstone Capital in August 2022 at a valuation of around Rs 2,500 crore, outbidding Max Healthcare. Everstone had bought the hospital chain three years earlier in 2019 from its founder, neurosurgeon Charudutt Apte, for about Rs 1,000 crore. The big money chasing Sahyadri for past several years is emblematic of the attraction Indian hospitals, especially smaller chains, have come to hold in recent times. Small-town hospitals are pulling big money Bulge-bracket private equity funds are increasingly investing in single-specialty Indian hospital chains that present a robust growth potential in emerging consuming centers, significantly widening the addressable market beyond their traditional metropolitan bailiwicks, ET had reported in April. Live Events Non-metro locations, such as Lucknow , Vizag, Jaipur, Cochin, Siliguri, Guwahati, Bhubaneswar and Patna, private equity investors believe, hold great growth potential in healthcare, in lockstep with an increasing affordability quotient in tier- 2 or 3 towns, and a greater availability of qualified doctors and specialists. PE funds are looking for players that will give higher returns - and blockbuster exits when the investments run their course. 'A trifecta of factors is helping accelerate investor interest in the single specialty healthcare chains including significant growth opportunity in tier 2/3 cities, clearly visible unit economics and viability with best in class ROIs,' Vishal Bali, executive chairman, Asia Healthcare Holdings (AHH), a leading healthcare investment platform, with focus on single specialities like oncology, women and child care, fertility, urology and nephrology, had told ET. 'AHH has been the inflection point for Single speciality healthcare with all our companies in single speciality healthcare delivering consistent growth in revenues, ebitda and geographical reach along with ROIs' he said. Parking PE monies in treatment areas such as IVF, nephrology, eye-care, oncology, mother & childcare among others, have become a credible prescription for future value creation, after nearly a decade-long hunt for multi-speciality assets across the country. According to an analysis done by Avendus, single-speciality hospitals account for over 40% of all PE investments in healthcare since 2019. This was just a bit over 15% between 2015 and 2018. Between 2020 and early 2025, the segment recorded 24 PE/VC investments totalling $1.8 billion, with 19 of those deals worth $1.2 billion closing in the last two years alone, shows data put together by Grant Thornton. Billions of dollars pour into hospital sector Over the period of two years from 2022-24 Hospitals in India have become one of the preferred investment destination for Investors, attracting net investment of $4.96 billion from Private Equity and $3.2 billion through Foreign Direct Investment (FDI). As per a report prepared by consultancy firm Grant Thornton Bharat in collaboration with the Association of Healthcare providers of India (AHPI), from 2022-24 hospitals in India undertook M&A deals worth $6.74 billion and attracted $4.96 billion from Private Equity (PE) investors. During the period, hospitals also raised $466 million through Initial Public Offering (IPO). The report which analysed 594 M&A and private equity transactions that took place during the period states that, 'Hospitals require diverse funding solutions to sustain growth, ranging from equity financing, debt financing, and foreign direct investment (FDI) to public-private partnerships (PPPs).' As per the investment analysis, the top three investment via PE route includes: Temasek Holdings $2 billion investment in Manipal Health (2023); $656 million by BPEA EQT in Indira IVF (2023); and lastly Blackstone Group $591.1 million investment in Quality Care (2023). A recent big deal was by a New York-based global private-equity and investment company, KKR, which in February bought a controlling stake in leading cancer care hospital chain Healthcare Global (HCG) from private equity peer CVC Capital Partners for nearly $400 million. By acquiring Baby Memorial Hospital last year, KKR made a comeback to the sector after one of its biggest paydays in India exiting Max Healthcare two years ago. Deal-making in India's healthcare sector has surged in recent years, with hospitals now commanding the largest share of foreign direct investment (FDI) within the sector, TOI had reported in December. In FY24, hospitals accounted for 50% of the FDI in total healthcare, translating to $1.5 billion. This marks a significant increase, as the share of hospitals in healthcare FDI has more than doubled from 24% in FY21, and has been rising from 43% in FY20, underscoring their growing prominence. The trend also reflects a strengthening investor preference for hospitals, alongside the traditionally favoured pharmaceuticals sector. The strong private equity interest in India's healthcare services companies is a highly credible indicator of the multi-decade growth potential inherent in the sector, as per a top executive at European investment bank Rothschild & Co. "We expect to see expansion of interest as international players evaluate the market and get more comfortable with the domestic landscape," Hedley Goldberg, partner and global head of healthcare services at Rothschild & Co, told ET in an interview in January. Besides a number of private equity deals, the hospital sector is also attracting big Indian businesses. While several corporates such as Tata , Birla and Hinduja have a presence in healthcare, none has made a significant pan-India presence. But the Bajaj Group is preparing to enter the healthcare sector by setting up a chain of hospitals in metros across the country., ET had reported last year. As per Bloomberg, it has earmarked Rs 10,000 crore as an initial investment. In recent years, healthcare companies and hospitals in India have been increasingly focussing on acquiring buildings and properties to expand their operations and strengthen their market presence. This trend is driven by the rising demand for quality healthcare services in urban and semi-urban areas, fuelled by a growing population, increasing health awareness and better insurance coverage. Hunt for stressed assets In December last year, billionaire Mukesh Ambani's Reliance Industries acquired technology-driven and oncology-focused healthcare platform Karkinos for Rs 375 crore. Reliance bought it under the Insolvency and Bankruptcy Code (IBC). The healthcare sector, particularly hospitals, witnessed major expansion during the Covid-19 pandemic. However, after the situation eased, it became difficult for many standalone hospitals to sustain their businesses. Such hospitals have been seeing interest from two sets of bidders — those already in the industry and seeking to expand and those who want to turn around such entities before they sell to someone else. Promoter-driven strategic investment firms and hospital operators are scouting for stressed healthcare assets that they can acquire through the insolvency and bankruptcy process, as private equity firms often edge them out in the race for good assets by offering lofty valuations. Why India's hospital sector has turned so hot Historically, the pharmaceuticals sector, including APIs (active pharmaceutical ingredients), has been the investor favourite, attracting multi-billion-dollar deals. However, post-Covid, the hospital and diagnostics sector has come into the spotlight, drawing a wave of investors. The Indian hospital sector market cap surged 9x from Rs 37,500 crore in FY20 to Rs 3.5 lakh crore, brokerage firm JM Financial said last year in July. At a time when the sector was grappling with inefficiencies, high leverage and low ROCEs, Covid provided a much-needed impetus. This came from improved pricing, higher insurance coverage and dedicated shift towards complex surgeries such as transplants. India's top listed hospital chains performed well in the stock market leading up to this year. Apollo Hospitals' shares climbed 28% in 2024, while Max Healthcare Institute Ltd. soared 64%. The Indian hospital industry is poised to post a healthy compound annual growth rate (CAGR) of about 12% over the next three fiscal years, credit rating agency CareEdge Ratings said last year. Growing incidence of lifestyle diseases and easing demand for affordable health care delivery are driving the healthcare market in India. A report released last year by HSBC Global Research on India hospitals said seven listed hospitals will add 14,000 beds in the next 3-5 years. A total of 22,000 new beds is expected, including those by other private hospital chains. Even with these additions, there will be no over-supply of beds in India. The report said that the addition of beds is triple the number of beds added between FY19-24 at 4,000. Most hospitals are now in a consolidation phase and planning to expand and add sees growth opportunities after making profits between FY19-24 because of low capex. A World Health Organisation (WHO) report said last year that India has only 16 beds per 10,000 people, which is abysmally low if compared with most of the developed and emerging markets. India requires 100,000 additional beds in the next 5-7 years just to meet its healthcare demand on the back of increasing non-communicable diseases such as diabetes, cardiac disorders, and cancer., as per the HSBC report. The government's push to turn India into a global healthcare hub by promoting medical tourism is another strong growth driver for the hospital sector.
Mint
32 minutes ago
- Mint
Stocks to buy: Adani Enterprises, Jio Financial to DLF — 10 stocks that can offer solid returns in second half of 2025
Stocks to buy: The Indian stock market has defied multiple hurdles to stage a sharp comeback in the first half of the calendar year 2025 after a tumultuous end to the last one. Trade war, India-Pakistan conflict, Iran-Israel war and earnings slowdown emerged as several headwinds which Nifty 50 overcame to record a nearly 8% jump in the first half of 2025 (H1 CY25). Going ahead, analysts remain hopeful about the Nifty 50's outlook and expect the index to hit new highs in H2 CY25. "On the fundamental front, the market is buoyed by expectations of strong Q1 FY26 earnings, continued policy support from the RBI, and pro-growth initiatives by the government. Positive developments on the international front, a normal monsoon forecast, easing geopolitical tensions, stable crude oil prices, and resilient domestic macroeconomic indicators, are likely to further bolster investor sentiment," said Vishnu Kant Upadhyay, AVP - Research & Advisory, Master Capital Services. Commenting on the technical outlook, Harshal Dasani, Research Analyst, INVasset PMS, said the second half of 2025 appears to be on firmer ground, with key global macro indicators slowly falling into place. "If current macro tailwinds hold steady, Nifty could comfortably scale 27,500 by the end of the year—even on a conservative basis. Unlike previous cycles, this rally is being built on improving internals, not just hope," Dasani said. Against this backdrop, analysts have shared several fundamental and technical stocks to buy for solid returns in H2 CY25. Here's a look: Adani Enterprises has broken out of an ascending triangle pattern with strong volume, trading above all key EMAs, indicating bullish momentum. RSI and MACD support further upside, with potential targets of 3080-3150. Analyst: Vishnu Kant Upadhyay, AVP - Research & Advisory, Master Capital Services Mahanagar Gas has given a breakout above trendline resistance with strong volume and a bullish EMA crossover. RSI near 68 and a rising MACD signal further upside potential towards 1670-1700. Analyst: Vishnu Kant Upadhyay, AVP - Research & Advisory, Master Capital Services Bandhan Bank has broken out of a multi-year falling channel on the weekly chart, signalling a trend reversal. RSI at 62 and a bullish MACD crossover support further upside towards 215. Analyst: Vishnu Kant Upadhyay, AVP - Research & Advisory, Master Capital Services Jio Financial has given a trendline breakout and is trading above key EMAs, indicating strong bullish momentum. RSI above 75 and bullish MACD crossover suggest further upside potential towards 370. Analyst: Vishnu Kant Upadhyay, AVP - Research & Advisory, Master Capital Services According to KOEL, the demand for high and mid-horsepower diesel gensets would be driven by the power generating segment as well as the expansion of the roadways and real estate sectors. Furthermore, it is anticipated that demand for electric pumps would increase as electricity becomes available in rural regions are well-positioned to take advantage of on-demand pickup. Additionally, the demand from roads, metro projects, railroads, etc., will propel sales in the industrial area. The distribution sector will also benefit from improvements in core operations and a rise in client outsourcing of maintenance services. Analyst: Anubhav Sangal, Senior Research Analyst at Bonanza With an order inflow of ₹ 4,700 crore in FY25, the company's order book was valued at ₹ 22,238 crore as of March 31, 25. With projects totalling ₹ 4,250 crore, the firm is L1. Revenue visibility is provided by a strong and healthy order book for the upcoming three to four years. Over FY25–FY27E, we anticipate that the company will report a revenue CAGR of 19%. Analyst: Anubhav Sangal, Senior Research Analyst at Bonanza DLF's record FY25 performance, with ₹ 21,000+ crore pre-sales, ₹ 11,750 crore collections, and ₹ 4,350 crore PAT, underscores its robust growth trajectory. A zero-leverage development business, double-digit ROE (10.2%), and a strong land bank position, DLF for sustained expansion. The FY26 pipeline, targeting ₹ 20,000–22,000 crore pre-sales and ₹ 5,000 crore annual RentCo capex, reflects confidence in NCR dominance and strategic expansions into Mumbai and Goa. With high demand for branded residential and premium commercial assets, DLF's dual-engine model, focusing on margins and cash flow, ensures resilience and long-term value creation. Analyst: Anubhav Sangal, Senior Research Analyst at Bonanza Hindustan Unilever has established a strong base around the ₹ 2300 level, which coincides with the S1 floor pivot and the previous breakout zone—both key technical supports. On the daily RSI chart, a complex W-shaped structure has emerged near the 40 mark, often indicative of a potential trend reversal and strengthening momentum. We recommend going long in the ₹ 2310– ₹ 2290 range. The upside target is placed at ₹ 2600, while a stop-loss should be maintained below ₹ 2150 on a daily closing basis. Analyst: Jigar S. Patel, Senior Manager of Equity Research, Anand Rathi VBL has recently formed a tweezer bottom near the ₹ 446– ₹ 447 zone, which aligns with the S1 monthly floor pivot—indicating strong support at lower levels. Additionally, the RSI on the daily chart is showing an impulsive V-shaped recovery from the oversold region near the 30 mark, suggesting a potential shift in momentum. We recommend initiating long positions in the ₹ 462– ₹ 460 range, with an upside target of ₹ 510. A stop-loss should be placed below ₹ 435 on a daily closing basis to manage risk effectively. Analyst: Jigar S. Patel, Senior Manager of Equity Research, Anand Rathi Voltas has recently broken out of a month-long consolidation phase, supported by a noticeable increase in volume—indicating strong accumulation interest. What makes this development technically significant is the Inside Value relationship formed during the consolidation, as the price action remained confined within the R3–S3 zone of the monthly Camarilla pivots. This structure, where the current month's pivots lie within the previous month's range, often precedes a powerful directional breakout. Strengthening the bullish outlook, the daily RSI has consistently remained above the 50 level and is currently positioned at 56, reflecting a build-up in momentum. Entry Zone: ₹ 1315– ₹ 1280 1315– 1280 Target: ₹ 1540 1540 Stop-loss: ₹ 1175 (on a daily closing basis) Disclaimer: This story is for educational purposes only. The views and recommendations made above are those of individual analysts or broking companies, and not of Mint. We advise investors to check with certified experts before making any investment decisions.
